Showing 1551-1560 of 4848 results for "".
- Valeant, Galderma Revise Agreement Termshttps://practicaldermatology.com/news/20121210-valeant_galderma_revise_agreement_terms/2459661/Valeant Pharmaceuticals International, Inc. reached agreement on terms of a revised North American aesthetics arrangement with Galderma S.A. Under the terms, Galderma will continue to supply Restylane and Perlane to Valeant, under the terms and co
Physician Spotlight: Jeffrey P. Callen, MD, FACP, FAAD, MACR
https://practicaldermatology.com/columns/physician-spotlight/physician-spotlight-jeffrey-p-callen-md-facp-faad-macr/20625/Understanding cutaneous manifestations of systemic diseasePhysician Spotlight: Jeffrey S. Dover, MD, FRCPC
https://practicaldermatology.com/columns/physician-spotlight/physician-spotlight-jeffrey-s-dover-md-frcpc/23854/Physician Spotlight: Robert S. Kirsner, MD, PhD, FAAD
https://practicaldermatology.com/columns/physician-spotlight/physician-spotlight-robert-s-kirsner-md-phd-faad/20319/It's time to get wound up about wound care.Terrence Keaney, MD, FAAD
https://practicaldermatology.com/topics/practice-management/terrence-keaney-md-faad/20644/Making the leap to private practice in 2017The Latest on Systemic Agents for Psoriasis: A Q&A With Jashin J. Wu, MD, FAAD
https://practicaldermatology.com/programs/practical-dermatology-focus-psoriasis/the-latest-on-systemic-agents-for-psoriasis/29073/The pharmacologic pipeline continues to produce strong options for systemic treatment of psoriasis. Practical Dermatology® spoke with Editorial Board member Jashin J. Wu, MD, FAAD, Founder and CEO of the Dermatology Research and Education Foundation, to discuss the latest treatment considerations wiPhysician Spotlight: Mark D. Kaufmann, MD, FAAD
https://practicaldermatology.com/columns/physician-spotlight/physician-spotlight-mark-d-kaufmann-md-faad/23682/IL-31’s Role in Prurigo Nodularis
https://practicaldermatology.com/videos/dermatology-hub-neuroimmune-network/il-31s-role-in-prurigo-nodularis/48804/Raj Chovatiya, MD, PhD, MSCI, FAAD, explains the role of the IL-31 pathway in neuroinflammatory disease such as prurigo nodularis.Charles Crutchfield III, MD, FAAD
https://practicaldermatology.com/topics/practice-management/charles-crutchfield-iii-md-faad/21433/Physician Spotlight: Valerie Harvey, MD, MPH, FAAD
https://practicaldermatology.com/columns/physician-spotlight/physician-spotlight-valerie-harvey-md-mph-faad/23595/